Comparison Brainstorm Cell Therapeutics (BCLI) with Competitors
Brainstorm Cell Therapeutics (BCLI) industry is Biotechnology.
Debt-to-Equity
BCLI-12.07%
Industry29.76%
Upside-41.83%
Free Cash Flow Yield
BCLI-86.94%
Industry-1.94%
Upside-85.00%
P/E
BCLI-0.78
Industry-18.88
Upside+1809.89%